JP2024518947A5 - - Google Patents
Info
- Publication number
- JP2024518947A5 JP2024518947A5 JP2023568726A JP2023568726A JP2024518947A5 JP 2024518947 A5 JP2024518947 A5 JP 2024518947A5 JP 2023568726 A JP2023568726 A JP 2023568726A JP 2023568726 A JP2023568726 A JP 2023568726A JP 2024518947 A5 JP2024518947 A5 JP 2024518947A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- agent
- composition according
- weeks
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163186569P | 2021-05-10 | 2021-05-10 | |
| US63/186,569 | 2021-05-10 | ||
| PCT/US2022/028135 WO2022240688A1 (en) | 2021-05-10 | 2022-05-06 | Dosing regimen for combination therapy targeting dll3 and pd-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518947A JP2024518947A (ja) | 2024-05-08 |
| JP2024518947A5 true JP2024518947A5 (enExample) | 2025-05-21 |
Family
ID=84029376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568726A Pending JP2024518947A (ja) | 2021-05-10 | 2022-05-06 | Ｄｌｌ３及びｐｄ－１を標的とする組み合わせ療法のための投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240317856A1 (enExample) |
| EP (1) | EP4337252A4 (enExample) |
| JP (1) | JP2024518947A (enExample) |
| KR (1) | KR20240006585A (enExample) |
| CN (1) | CN117377488A (enExample) |
| AU (1) | AU2022273509A1 (enExample) |
| CA (1) | CA3217141A1 (enExample) |
| CL (1) | CL2023003357A1 (enExample) |
| IL (1) | IL307646A (enExample) |
| MX (1) | MX2023013227A (enExample) |
| TW (1) | TW202309092A (enExample) |
| WO (1) | WO2022240688A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| KR20240153575A (ko) * | 2022-02-23 | 2024-10-23 | 암젠 인크 | Dll3을 표적화하는 암 치료 |
| WO2024123965A2 (en) * | 2022-12-08 | 2024-06-13 | Amgen Inc. | Methods for treating dll3-expressing cancer |
| EP4712977A1 (en) * | 2023-05-19 | 2026-03-25 | Boehringer Ingelheim International GmbH | Uses of t cell engaging proteins in the treatment of cancer |
| CN120168667B (zh) * | 2025-03-18 | 2026-04-14 | 中国科学院近代物理研究所 | 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| JP7479290B2 (ja) * | 2018-04-10 | 2024-05-08 | アムジエン・インコーポレーテツド | Ｄｌｌ３に対するキメラ受容体及びその使用方法 |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
-
2022
- 2022-05-06 IL IL307646A patent/IL307646A/en unknown
- 2022-05-06 EP EP22808092.5A patent/EP4337252A4/en active Pending
- 2022-05-06 WO PCT/US2022/028135 patent/WO2022240688A1/en not_active Ceased
- 2022-05-06 US US18/289,317 patent/US20240317856A1/en active Pending
- 2022-05-06 AU AU2022273509A patent/AU2022273509A1/en active Pending
- 2022-05-06 CA CA3217141A patent/CA3217141A1/en active Pending
- 2022-05-06 KR KR1020237041314A patent/KR20240006585A/ko active Pending
- 2022-05-06 CN CN202280031401.6A patent/CN117377488A/zh active Pending
- 2022-05-06 JP JP2023568726A patent/JP2024518947A/ja active Pending
- 2022-05-06 MX MX2023013227A patent/MX2023013227A/es unknown
- 2022-05-10 TW TW111117458A patent/TW202309092A/zh unknown
-
2023
- 2023-11-10 CL CL2023003357A patent/CL2023003357A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518947A5 (enExample) | ||
| JP2023501375A5 (enExample) | ||
| JP2025508786A5 (enExample) | ||
| CA2867343C (en) | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| JP2022525149A5 (enExample) | ||
| JP2011511071A5 (enExample) | ||
| JP2021535161A5 (enExample) | ||
| JP2022544485A5 (enExample) | ||
| JP2024542682A5 (enExample) | ||
| JPWO2020250915A5 (enExample) | ||
| JP2022501332A5 (enExample) | ||
| Moe et al. | High dose methotrexate in acute lymphocytic leukemia in childhood | |
| Cornwell et al. | Hypersensitivity reactions to IV melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience | |
| JP2022514561A5 (enExample) | ||
| ES2935265T3 (es) | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control | |
| JP2024540044A5 (enExample) | ||
| JP2023521853A5 (enExample) | ||
| JP2025521501A5 (enExample) | ||
| IL317954A (en) | Treatment of hematological malignancies with galectin-9 inhibitory antibodies | |
| Beisel | Alterations in hormone production and utilization during infection | |
| CA1189792A (en) | Adrenosteroid composition and method for the treatment of shock by infusional therapy | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| JP2025126668A (ja) | 人免疫グロブリンｇを有効成分として含有する、腎臓移植後の抗体関連型拒絶反応の治療剤 | |
| WO2019231800A1 (en) | Anti-cgrp antibodies for treating menstrual-related migraines | |
| JP2002506051A (ja) | Ｈｉｖ−１感染を治療するための放射免疫剤 |